BHV 7000
Alternative Names: BHV-7000; BPN-25203; KB-3061Latest Information Update: 22 Mar 2025
At a glance
- Originator Channel Biosciences
- Developer Biohaven Pharmaceuticals
- Class Amides; Analgesics; Antidepressants; Antiepileptic drugs; Benzimidazoles; Mood stabilisers; Neuropsychotherapeutics; Small molecules
- Mechanism of Action KCNQ2 potassium channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Bipolar disorders; Epilepsy; Partial epilepsies
- Phase II Major depressive disorder
- Phase I Infantile spasms; Mood disorders; Pain
Most Recent Events
- 30 Jan 2025 Biohaven Therapeutics completes phase-II/III clinical trials in Bipolar disorders (In adults, In the elderly) in USA (NCT06419582)
- 16 Dec 2024 Biohaven Therapeutics completes enrolment in a phase II/III trial in Bipolar disorders in USA before December 20-2024 (NCT06419582)
- 06 Dec 2024 Pharmacodynamics data from a preclinical trial in Epilepsy released by Biohaven Pharmaceuticals